Deadline Alert: Ardent Health, Inc. (ARDT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit — Neutral
ARDT GlobeNewsWire — January 30, 2026LOS ANGELES, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming March 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”).
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug — Negative
LENZ Benzinga — January 30, 2026On Wednesday, the U.S. Food and Drug Administration (FDA) approved Tenpoint Therapeutics Ltd.'s Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop for presbyopia in adults.
Lululemon price target slashed on outgoing CEO's final day — Negative
LULU Proactive Investors — January 30, 2026Jefferies analysts lowered their price target on Lululemon Athletica Inc (NASDAQ:LULU) stock to $185 from $200, coinciding with the outgoing CEO Calvin McDonald's final day at the company. Shares of Lululemon traded at about $174 on Friday, down almost 60% in the last 12 months.
Can Operational Execution Support DaVita's Q4 Performance? — Positive
DVA Zacks Investment Research — January 30, 2026DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
CMCSA Q4 Earnings Beat On Theme Parks and Peacock Strength — Positive
CMCSA Zacks Investment Research — January 30, 2026Comcast tops Q4 EPS and revenues as Theme Parks and Peacock surge, offset by broadband losses, weaker Studios results and margin pressure.
Schneider Q4 Earnings Miss Estimates, Down Year Over Year — Negative
SNDR Zacks Investment Research — January 30, 2026SNDR reports Q4 earnings miss as softer demand and higher costs weigh on results. It expects its 2026 EPS to be in the range of 70 cents-$1.00.
All You Need to Know About 1st Source (SRCE) Rating Upgrade to Buy — Positive
SRCE Zacks Investment Research — January 30, 20261st Source (SRCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WisdomTree, Inc. (WT) Reports Q4 Earnings: What Key Metrics Have to Say — Positive
WT Zacks Investment Research — January 30, 2026The headline numbers for WisdomTree, Inc. (WT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Innovex International (INVX) is a Great Momentum Stock: Should You Buy? — Positive
INVX Zacks Investment Research — January 30, 2026Does Innovex International (INVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Oceaneering International (OII) Upgraded to Strong Buy: What Does It Mean for the Stock? — Positive
OII Zacks Investment Research — January 30, 2026Oceaneering International (OII) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Brookfield Renewable (BEP) Reports Q4 Earnings: What Key Metrics Have to Say — Neutral
BEP Zacks Investment Research — January 30, 2026While the top- and bottom-line numbers for Brookfield Renewable (BEP) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SQM (SQM) Is Up 10.19% in One Week: What You Should Know — Positive
SQM Zacks Investment Research — January 30, 2026Does SQM (SQM) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Trupanion (TRUP) Rating Upgrade to Strong Buy — Positive
TRUP Zacks Investment Research — January 30, 2026Trupanion (TRUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Sibanye Gold Limited (SBSW) is a Great Momentum Stock: Should You Buy? — Positive
SBSW Zacks Investment Research — January 30, 2026Does Sibanye Gold Limited (SBSW) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? — Positive
CABA Zacks Investment Research — January 30, 2026Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.
QCR Holdings (QCRH) Upgraded to Buy: What Does It Mean for the Stock? — Positive
QCRH Zacks Investment Research — January 30, 2026QCR Holdings (QCRH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know — Positive
SANA Zacks Investment Research — January 30, 2026Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Monday.com (MNDY) Upgraded to Buy: Here's Why — Positive
MNDY Zacks Investment Research — January 30, 2026Monday.com (MNDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adtalem (ATGE) Upgraded to Buy: Here's What You Should Know — Positive
ATGE Zacks Investment Research — January 30, 2026Adtalem (ATGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avidbank Holdings, Inc. (AVBH) Q4 2025 Earnings Call Transcript — Neutral
AVBH Seeking Alpha — January 30, 2026Avidbank Holdings, Inc. (AVBH) Q4 2025 Earnings Call Transcript
